The short version
- The FDA approved daraxonrasib, sold as Rasonque, more than six months ahead of schedule after trials showed it nearly doubled median survival time compared to standard chemotherapy.
- The medication targets Kras gene mutations found in over 90% of pancreatic cancer cases, overcoming a biological barrier that had previously made these tumors resistant to targeted therapies.
- Public attention from high-profile patients contributed to expanded access programs prior to official approval, while researchers view this as a potential catalyst for developing treatments for other cancers.
The US Food and Drug Administration has granted expedited approval to a new oral medication designed to treat the most common form of pancreatic cancer. The drug, known generically as daraxonrasib and marketed under the brand name Rasonque by Revolution Medicines, represents a significant departure from traditional chemotherapy approaches. Regulators cleared the treatment more than six months ahead of their original target date, citing the urgent need for effective interventions against a disease that remains one of the deadliest forms of cancer in the United States.
Pancreatic cancer is notoriously difficult to treat because it often goes undetected until it has spread to other organs. According to estimates from the American Cancer Society, approximately 67,000 new cases are diagnosed annually in the US, with more than 52,000 deaths expected this year alone. The five-year overall survival rate stands at just 13%, reflecting the limited efficacy of existing treatments. Unlike other cancers that have seen a proliferation of therapeutic options, pancreatic cancer has resisted many conventional drug development strategies due to its complex biology and aggressive nature.
The newly approved medication targets mutations in the Ras gene family, which normally regulates cell growth but becomes dysregulated in cancer. Specifically, it addresses Kras mutations, which are present in more than 90% of pancreatic cancer cases. For decades, these mutated proteins were considered undruggable because their structure prevented medications from binding effectively to inhibit tumor growth. Revolution Medicines developed a molecular mechanism that acts as a glue, allowing the pill to bind with multiple subtypes of the Kras protein and block the signals that fuel cancer progression.
Clinical data supporting the approval came from a company-funded study involving 500 patients whose metastatic cancer had stopped responding to prior treatments. Participants were randomly assigned to receive either the experimental pill or standard chemotherapy. The results indicated a substantial improvement in outcomes for those taking daraxonrasib. Patients on the new treatment lived a median of 13.2 months, compared to 6.7 months for those receiving chemotherapy. Additionally, the study reported fewer severe side effects among patients using the targeted therapy, suggesting a potentially better quality of life during treatment.
The path to approval was influenced by growing public interest in the drug earlier this year. Former US Senator Ben Sasse of Nebraska publicly discussed his experience with the medication on CBS’s 60 Minutes program, noting reduced pain levels while undergoing treatment. This visibility prompted the FDA to allow expanded access for patients meeting specific criteria before the official clearance was finalized. Kyle Diamantas, the acting commissioner of the FDA, emphasized the agency’s commitment to delivering meaningful treatments quickly, stating that providing cures and effective therapies is a fundamental duty.
Medical professionals treating pancreatic cancer have expressed cautious optimism about the implications of this approval. Many view it as a potential turning point that could accelerate the development of additional therapeutic options. Dozens of experimental drugs are currently in various stages of development, and success with daraxonrasib may encourage further investment in targeting similar biological pathways. The ability to effectively inhibit Kras mutations opens new avenues for research that were previously considered too challenging or unlikely to succeed.
Revolution Medicines, based in Redwood City, California, is also exploring the application of this technology beyond pancreatic cancer. The company is studying its molecular binding approach for other forms of malignancy, including lung cancer, which may share similar genetic drivers. If successful in these additional contexts, the underlying mechanism could broaden the scope of targeted therapies available to patients with different types of advanced disease. This expansion would represent a significant advancement in precision medicine.
While the approval marks a notable achievement, challenges remain regarding long-term efficacy and broader accessibility. The study population consisted of patients whose cancer had already progressed and failed to respond to earlier treatments, meaning the drug’s impact on earlier-stage disease is not yet fully understood. Ongoing monitoring will be essential to assess how well the medication performs in diverse patient groups and whether it can sustain its benefits over extended periods. Healthcare providers are now preparing to integrate this new option into their treatment protocols while continuing to evaluate its role within the broader landscape of cancer care.
Sources behind this briefing
Go to the original reporting
- The Guardian US↗FDA gives expedited approval to new groundbreaking pancreatic cancer drug
